World Health Organization site
Skip Navigation Links

Main
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register.
Register: EUCTR
Last refreshed on: 19 April 2022
Main ID:  EUCTR2014-002475-29-NL
Date of registration: 08/12/2014
Prospective Registration: Yes
Primary sponsor: Gilead Sciences, Inc.
Public title: A Phase 2 clinical trial investigating the anti-virus effects, kinetics and safety of GS-5806 in adults with RSV (Respiratory Syncytial Virus) infection.
Scientific title: A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Multi-Center Study Evaluating Antiviral Effects, Pharmacokinetics, Safety, and Tolerability of GS-5806 in Hematopoietic Cell Transplant (HCT) Recipients with Respiratory Syncytial Virus (RSV) Infection of the Lower Respiratory Tract
Date of first enrolment: 10/02/2015
Target sample size: 60
Recruitment status: Not Recruiting
URL:  https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2014-002475-29
Study type:  Interventional clinical trial of medicinal product
Study design:  Controlled: yes
Randomised: yes
Open: no
Single blind: no
Double blind: yes
Parallel group: yes
Cross over: no
Other: no
If controlled, specify comparator, Other Medicinial Product: no
Placebo: yes
Other: no
Number of treatment arms in the trial: 2
 
Phase:  Human pharmacology (Phase I): no Therapeutic exploratory (Phase II): yes Therapeutic confirmatory - (Phase III): no Therapeutic use (Phase IV): no
Countries of recruitment
Australia Canada France Germany Israel Korea, Republic of Netherlands Poland
Sweden Taiwan United Kingdom United States
Contacts
Name: Clinical Trials Mailbox   
Address:  Flowers Building, Granta Park, Abington CB21 6GT Cambridge United Kingdom
Telephone: +441223897284
Email: clinical.trials@gilead.com
Affiliation:  Gilead Sciences International Ltd.
Name: Clinical Trials Mailbox   
Address:  Flowers Building, Granta Park, Abington CB21 6GT Cambridge United Kingdom
Telephone: +441223897284
Email: clinical.trials@gilead.com
Affiliation:  Gilead Sciences International Ltd.
Key inclusion & exclusion criteria
Inclusion criteria:
1. Males and females 18 to 75 years of age
2. Received an autologous or allogeneic HCT using any conditioning regimen
3. Evidence of new abnormalities on chest X-ray obtained < 48 hours prior to Screening, determined to be consistent with LRTI by the local radiologist, relative to the most recent chest X-ray. If chest X-ray is not available, a chest X-ray must be obtained for Screening.
4. Documented RSV in both the upper (eg, nasal swab, nasopharyngeal swab, nasal wash) and lower (eg, induced sputum, BAL, lung biopsy, but not spontaneous sputum) respiratory tract as determined by local testing (eg, PCR, DFA, RVP assay, or culture). All samples must have been collected = 6 days prior to Day 1 or as determined at Screening as per Section 6.1.1.
5. An informed consent document signed and dated by the subject or a legal guardian of the subject and investigator or his/her designee. In Sweden ICFs signed by legal guardian must also be signed by a close relative of the subject.
6. A negative urine or serum pregnancy test is required for female subjects (unless surgically sterile or greater than two years post-menopausal)
7. Male and female subjects of childbearing potential must agree to contraceptive requirements as described in Appendix 5
8. Willingness to complete necessary study procedures and have available a working telephone or email
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 15
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 45

Exclusion criteria:
Related to concomitant or previous medication use:
1. Use of non-marketed (according to region) investigational agents within 30 days, OR use of any investigational monoclonal anti-RSV antibodies within 4 months or 5 half-lives of screening, whichever is longer, OR use of any investigational RSV vaccines after HCT
2. Use of a moderate or strong cytochrome P450 enzyme (CYP) inducer including but not limited to rifampin, St. John’s Wort, carbamazepine, and phenytoin, efavirenz, bosentan, etravirine, modafinil, and nafcillin, within 2 weeks prior to the first dose of IMP
Related to medical history:
3. Pregnant, breastfeeding, or lactating females
4. Unable to tolerate nasal sampling required for this study, as determined by the investigator
5. Known history of HIV/AIDS with a CD4 count <200 cells/µL within the last month
6. History of drug and/or alcohol abuse that, in the opinion of the investigator, may prevent adherence to study activities
Related to medical conditions:
7. Requiring invasive mechanical ventilation at the time of randomization
8. Documented to be positive for other respiratory viruses (limited to influenza, parainfluenza, human rhinovirus, adenovirus, human metapneumovirus or coronavirus), from the lower respiratory tract sample as determined by local testing
9. Clinically significant bacteremia or fungemia within 7 days prior to Screening that has not been adequately treated, as determined by the investigator
10. Clinically significant bacterial, fungal, or viral pneumonia within 2 weeks prior to Screening that has not been adequately treated, as determined by the investigator
11. Excessive nausea/vomiting at screening, as determined by the investigator, or an inability to swallow pills that precludes oral administration of the IMP (for subjects without an NG tube in place)
12. Any condition which, in the opinion of the investigator, would prevent full participation in this trial or would interfere with the evaluation of the trial endpoints
Related to allergies:
13. Known hypersensitivity or allergy to the IMP, its metabolites, or formulation excipients (microcrystalline cellulose, mannitol, croscarmellose sodium, magnesium stearate, polyvinyl alcohol, titanium dioxide, polyethylene glycol and talc)
14. History of hypersensitivity, anaphylactic reaction, Stevens-Johnson Syndrome, or toxic epidermal necrolysis response to sulfa drugs
Related to laboratory results:
15. Creatinine clearance < 30 mL/min (calculated using the Cockcroft-Gault method)
16. Clinically significant AST/ALT, as determined by the investigator
17. Clinically significant TB, as determined by the investigator


Age minimum:
Age maximum:
Gender:
Female: yes
Male: yes
Health Condition(s) or Problem(s) studied
Respiratory Syncytial Virus (RSV) Infection of the lower respiratory tract.
MedDRA version: 19.0 Level: LLT Classification code 10039247 Term: RSV infection System Organ Class: 100000004862
Therapeutic area: Diseases [C] - Virus Diseases [C02]
Intervention(s)

Product Name: GS-5806
Product Code: GS-5806
Pharmaceutical Form: Film-coated tablet
INN or Proposed INN: Presatovir
CAS Number: 1353625-73-6
Current Sponsor code: GS-5806
Other descriptive name: GS-5806
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 50-
Pharmaceutical form of the placebo: Film-coated tablet
Route of administration of the placebo: Oral use

Primary Outcome(s)
Main Objective: To evaluate the effect of presatovir on RSV viral load in autologous or allogeneic HCT recipients with an acute RSV LRTI
Secondary Objective: - To evaluate the effect of presatovir on being free of any supplemental oxygen, and rates of respiratory failure and all cause mortality
- To evaluate the PK, safety, and tolerability of presatovir
Primary end point(s): Time-weighted average change in nasal RSV viral load (log10 copies/mL) from Baseline (Day 1) to Day 9 as measured by RT-qPCR
Timepoint(s) of evaluation of this end point: Day 1 to day 9 (daily measure)
Secondary Outcome(s)
Secondary end point(s): - Number of supplemental O2 free days through Day 28
- Proportion of subjects developing respiratory failure (of any cause) requiring mechanical
ventilation (invasive or noninvasive) through Day 28
- Proportion of all-cause mortality among subjects through Day 28
Timepoint(s) of evaluation of this end point: Day 28.
Secondary ID(s)
GS-US-218-1502
Source(s) of Monetary Support
Gilead Sciences, Inc.
Secondary Sponsor(s)
Ethics review
Status: Approved
Approval date: 10/02/2015
Contact:
Results
Results available: Yes
Date Posted: 12/04/2018
Date Completed: 17/04/2017
URL: https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-002475-29/results
Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.
Copyright - World Health Organization - Version 3.6 - Version history